Top Markets
Coin of the day
Valion Bio, Inc. Valion Bio, Inc.

Valion Bio, Inc.

VBIO
Rang in Aktien #38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Aktienkurs
$0.1645
Marktkapitalisierung
$681.26K
Veränderung (1 Tag)
-3.69%
Veränderung (1 Jahr)
-95.30%
Land
US
Handel Valion Bio, Inc. (VBIO)

Kategorie

Dividendenrendite-Verlauf für Valion Bio, Inc. (VBIO)
Dividendenrendite (TTM) von Valion Bio, Inc. (Aktienkürzel: VBIO) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Valion Bio, Inc. (VBIO) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber